| Badgettrg/Malignant hypertensionTemp |
|---|
Diagnosis edit
Treatment edit
In the past, the prophylactic use of dantrolene was recommended for MH susceptible patients undergoing general anesthesia.[1] However, multiple retrospective studies, have demonstrated the safety of trigger-free general anesthesia in these patients in the absence of prophylactic dantrolene administration. The largest of these studies looked at the charts of 2214 patients who underwent general or regional anesthesia for an elective muscle biopsy. 1082 of the patients were muscle biopsy positive for MH. Only five of these patients exhibited symptoms consistent with MH, four of which were treated successfully with parenteral dantrolene, and the remaining one recovered with only symptomatic therapy.[2] After weighing its questionable benefits against its possible adverse effects, experts no longer recommend the use of prophylactic dantrolene prior to trigger-free general anesthesia in MH susceptible patients.[3]
References edit
- ^ T. Krause, M. U. Gerbershagen, M. Fiege, R. Weißhorn, F. Wappler (2004) Dantrolene - A review of its pharmacology, therapeutic use and new developments Anaesthesia 59 (4) , 364–373
- ^ Carr AS, Lerman J, Cunliffe M, McLeod ME, Britt BA . Incidence of malignant hyperthermia reactions in 2214 patients undergoing muscle biopsy. Canadian Journal of Anaesthesia 1995; 42: 281– 6.
- ^ T. Krause, M. U. Gerbershagen, M. Fiege, R. Weißhorn, F. Wappler (2004) Dantrolene - A review of its pharmacology, therapeutic use and new developments Anaesthesia 59 (4) , 364–373